A review of recent trends and remaining challenges in bispecific antibody (bsAb) production has been published.

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in lymphoma research.

prompting the creation of multispecific antibodies, which include bispecific, trispecific, and tetraspecific antibodies. Among these, bispecific antibodies, capable of binding to two distinct epitopes ...

Bispecific antibodies represent an innovative paradigm in cancer therapy, offering broader therapeutic potential compared to conventional monoclonal antibodies. To increase tumor selectivity while ...

Orion Corporation ("Orion"), a globally operating pharmaceutical company, and Invenra Inc., an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today ...

Orion Corporation (“Orion”) and Invenra Inc. (“Invenra”), an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today announced that they have entered ...

Jeffrey V. Matous, MD, discusses how best practices in transitioning care between academic and community centers can enhance patient outcomes when receiving bispecific antibodies, and the critical ...

NR- not reported NR*- not reached Clinical outcome data with use of bispecific antibodies.

Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal ...

MSD has an extensive pipeline in oncology but hasn't been a player in bispecific antibodies. Now, it has bolted on a bispecific via a $1.3 billion licensing deal with Curon Biopharma. The big ...